The briefing provides an at-a-glance-view of some important developments in the information universe surrounding COVID-19. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders

Download this Scan

ECRI Horizon Scanning has selected the topics below as those with potential for impact relative to COVID-19 in the United States within the next 12 months. All views presented are preliminary and based on readily available information at the time of writing.

Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.

Accula SARS-CoV-2 Point-of-Care Test to Diagnose COVID-19

At a Glance

  • The Accula SARS-CoV-2 test is intended for point-of-care testing with laboratory-quality results in about 30 minutes from nasal and throat swabs and might be used in temporary screening facilities, ambulatory care facilities, and long-term care facilities.  
  • The test demonstrated sensitivity of 68% and specificity of 100% in 100 nasopharyngeal samples previously tested by the SARS-CoV-2 PCR Assay.
  • FDA granted the Accula SARS-CoV-2 test Emergency Use Authorization in March 2020.

CoviTact Point-of-Care Protease Assay to Diagnose COVID-19

At a Glance

  • CoviTact is an investigational point-of-care test intended to detect SARS-CoV-2 in saliva samples, nasal swabs, or other body fluids.
  • CoviTact reagents exploit the virus’s enzymatic activity to detect the presence of the virus within minutes and can be used in temporary screening facilities, ambulatory care facilities, and long-term care facilities.

Dexamethasone to Treat Severe COVID-19

At a Glance

  • Dexamethasone is a commercially available corticosteroid that might provide an intravenous or oral treatment option for reducing severe COVID-19 hyperinflammation.
  • Hospitalized patients on ventilation given dexamethasone had a one-third decrease in deaths compared with patients given standard care, and patients only receiving oxygen and given dexamethasone had a one-fifth decrease in deaths compared with standard care.
  • Based on available clinical trial dosing and pricing information, a course of dexamethasone for treating severe COVID-19 could cost between about $9 and $21.

We welcome your comments on this Scan. Send them by email to [email protected] or
by mail to: Patient-Centered Outcomes Research Institute, 1828 L Street, NW, Suite 900, Washington, DC 20036.

Commentary in this COVID-19 Scan reflects preliminary views of ECRI Horizon Scanning and internal ECRI stakeholders. This information contained in this document has not been vetted by other stakeholders.


Posted: June 30, 2020

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails highlighting results of our funded studies, newly funded research and engagement awards, opportunities to apply for funding, stakeholder workshops, and original feature stories about our funded projects.

Sign Up for Updates

Image

Hand pointing to email icon